You are here:
Horizonscan geneesmiddelen
Beheer
Management
Apps
Logged in as Riwka Rubinstein
Search the site
Medicines
General
Concepts
News
Processes
Newsletters
Portfolio holders
Settings
Zorginstituut Nederland
Zorginstituut Nederland
Oncologie
Hematologie
Bookmarks
Open/Close
Medicines
Aripazine
Opdivo
Concepts
Begrippenlijst
News
Aanlevering kwaliteitsgegevens verpleeghuiszorg
Risico-informatie over fludarabine
Drafts
Open/Close
Medicines
niet bekend
Zelboraf
Ocaliva
Lokelma
Scenesse
Kanuma
Kolbam
Galafold
Strensiq
Glyxambi
Jardiance
Incredible new medicine
BS
Yervoy
IND
Ipilimumab
BS
Onbekend
Perjeta
Zelboraf
Opdivo
General
Achtergrond
Concepts
Algemene Verordening Gegevensbescherming
Begrippenlijst
News
Publicatie specificaties revisierelease iWmo en iJw 3.0.3
Processes
Contributing a record
Sluice medicines
Open/Close
Meets sluice criteria
VeliparibBrain metastases from NSCLC
Nivolumab
Sluice candidates
Wondermiddel
BS
Included in the sluice
Regorafenib
Obinutuzumab
IbrutinibMantle cell lymphoma (MCL), 1L
TremelimumabNon-small cell lung cancer (NSCLC), stage IV, in combination with durvalumab, 1L
Olaparib
Nivolumab
Pembrolizumab
Denosumab
Nivolumab
Wijzigingsverzoeken
Roche
Nivolumab
Alectinib
Pertuzumab
Ter beoordeling door fabrikant
Roche
Vemurafenib
Nieuw van Fabrikanten
Roche
coronine
For review
Medicines
Onbekend
News flashes
Conferentie in Carré
Approved
News
Risico-informatie over fluorochinolonen
News flashes
Zorginstituut Nederland verhuist naar groot pand aan de Herengracht
National Health Care Institute
My profile
Bookmarks
Preferences
Change password
Log out
Understanding of expected market entry
of innovative medicines
Service
Contact
Glossary
Newsletter
Newsletter archive
Processes
About this site
Proclaimer
Copyright
Cookies
Kwetsbaarheid melden